Hospital
Bon Secours Memorial Regional Medical Center LLC
Bon Secours Memorial Regional Medical Center LLC was paid $42.02M by Medicaid between Jan 2018 and Dec 2024, across 345 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoBON SECOURS MEMORIAL REGIONAL MEDICAL CENTER LLC
MECHANICSVILLE, VA 23116
MECHANICSVILLE, VA 23116
33aNPI1912969064assigned 04/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$42.02M
24GClaims1,152,006
24DCodes billed345
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#20 of 80
Median peer was paid$14.69M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 137,679 | $3.51M | |
| 2019 | 162,467 | $4.36M | |
| 2020 | 137,548 | $4.64M | |
| 2021 | 167,722 | $5.20M | |
| 2022 | 161,778 | $6.03M | |
| 2023 | 207,965 | $9.02M | |
| 2024incomplete | 176,847 | $9.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 38,129 | 33,055 | $5.72M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 33,134 | 27,727 | $5.20M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.8% | 26,242 | 21,698 | $4.14M |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.9% | 12,933 | 9,980 | $3.33M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.1% | 35,065 | 26,267 | $2.97M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.9% | 9,439 | 8,189 | $2.06M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 10,933 | 9,515 | $1.41M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 9,037 | 7,643 | $1.32M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.9% | 3,169 | 2,709 | $1.21M |
| G0378 | Hospital observation service, per hour | 2.1% | 6,420 | 3,492 | $872K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 2.1% | 1,381 | 1,208 | $864K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 2.0% | 1,207 | 1,110 | $843K |
333 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 3,457 | $628K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 2,833 | $621K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.3% | 1,050 | $567K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.2% | 2,369 | $486K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 5,981 | $451K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 9,902 | $429K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 6,912 | $421K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 14 | $413K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,530 | $397K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,153 | $343K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,164 | $309K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,290 | $305K |
| 59025 | Fetal non-stress test | <1% | 1,916 | $273K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,573 | $271K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,902 | $243K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,886 | $238K |
| 93971 | <1% | 2,475 | $215K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,535 | $199K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 1,222 | $193K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 340 | $187K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,880 | $185K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,250 | $184K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,204 | $181K |
| 70496 | <1% | 714 | $172K | |
| 80053 | Comprehensive metabolic panel | <1% | 51,276 | $170K |
| 97162 | <1% | 1,344 | $157K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,539 | $133K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,262 | $132K |
| 76642 | <1% | 1,202 | $123K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 772 | $115K |
| 97161 | <1% | 1,793 | $113K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,699 | $112K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 651 | $109K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 665 | $107K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 667 | $101K |
| 72141 | <1% | 597 | $97K | |
| 93458 | <1% | 75 | $95K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 412 | $85K |
| 76536 | <1% | 770 | $81K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,013 | $71K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 575 | $67K |
| 71250 | <1% | 994 | $63K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,945 | $63K |
| 93970 | <1% | 538 | $62K | |
| 95806 | <1% | 112 | $57K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 322 | $57K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,155 | $53K |
| 97803 | <1% | 543 | $52K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 400 | $48K |
| 81025 | <1% | 17,170 | $46K | |
| 99385 | <1% | 304 | $45K | |
| 83880 | <1% | 6,317 | $41K | |
| 97116 | <1% | 1,798 | $40K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,952 | $40K |
| 90677 | <1% | 756 | $39K | |
| 71271 | <1% | 375 | $37K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 30,082 | $35K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 242 | $34K |
| 72100 | <1% | 2,572 | $33K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 475 | $32K |
| 97165 | <1% | 652 | $32K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,350 | $31K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,546 | $31K |
| J2704 | Injection, propofol, 10 mg | <1% | 15,072 | $31K |
| 99384 | <1% | 196 | $30K | |
| 74018 | <1% | 1,759 | $30K | |
| 64721 | <1% | 29 | $29K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,568 | $29K |
| 73030 | <1% | 2,263 | $26K | |
| 70491 | <1% | 108 | $25K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 64,412 | $25K |
| 93798 | <1% | 247 | $25K | |
| 87040 | <1% | 4,298 | $24K | |
| 76770 | <1% | 208 | $22K | |
| 84484 | <1% | 23,789 | $22K | |
| 90715 | <1% | 1,248 | $22K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 169 | $22K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 27,158 | $21K |
| 81001 | <1% | 35,664 | $21K | |
| 73562 | <1% | 2,692 | $21K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,154 | $21K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,093 | $20K |
| 99153 | Mod sedat endo service >5yrs | <1% | 593 | $20K |
| 96127 | <1% | 754 | $20K | |
| 73502 | <1% | 1,582 | $19K | |
| 29581 | <1% | 125 | $19K | |
| 70498 | <1% | 752 | $19K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 210 | $19K |
| 82962 | <1% | 19,519 | $19K | |
| 95816 | <1% | 110 | $19K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 763 | $17K |
| G0008 | Administration of influenza virus vaccine | <1% | 3,507 | $17K |
| 77066 | Tomosynthesis, mammo | <1% | 402 | $16K |
| 90674 | <1% | 722 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 421 | $16K |
| 73630 | <1% | 1,835 | $15K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,961 | $15K |
| 73130 | <1% | 1,364 | $14K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 27 | $14K |
| 99218 | <1% | 1,330 | $14K | |
| 73610 | <1% | 1,868 | $14K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,158 | $13K |
| 85379 | <1% | 3,262 | $13K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 52,743 | $12K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,682 | $12K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,429 | $12K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 26,888 | $11K |
| 90661 | <1% | 421 | $11K | |
| 95811 | <1% | 15 | $11K | |
| 95800 | <1% | 71 | $11K | |
| 77065 | Tomosynthesis, mammo | <1% | 265 | $10K |
| 85027 | <1% | 6,872 | $10K | |
| 99383 | <1% | 74 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 22,270 | $10K |
| S9472 | Cardiac rehabilitation program, non-physician provider, per diem | <1% | 58 | $10K |
| 90651 | <1% | 631 | $10K | |
| 88304 | <1% | 601 | $10K | |
| 64415 | <1% | 38 | $9K | |
| 83605 | <1% | 5,168 | $9K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 216 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,680 | $9K |
| 83655 | <1% | 488 | $9K | |
| 72050 | <1% | 526 | $9K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 129 | $9K |
| 74178 | <1% | 40 | $9K | |
| 73221 | <1% | 45 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 836 | $8K |
| 73564 | <1% | 178 | $7K | |
| 83690 | <1% | 14,072 | $7K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 293 | $7K |
| 12001 | <1% | 40 | $7K | |
| 86850 | <1% | 3,783 | $6K | |
| 90686 | <1% | 1,002 | $6K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,547 | $6K |
| 73110 | <1% | 690 | $6K | |
| 70486 | <1% | 141 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 19,380 | $6K |
| 82553 | <1% | 1,531 | $5K | |
| 93017 | <1% | 39 | $5K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $5K |
| 73560 | <1% | 217 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,707 | $5K |
| 80047 | <1% | 1,067 | $5K | |
| 72131 | <1% | 49 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,372 | $5K |
| J3490 | Unclassified drugs | <1% | 11,246 | $5K |
| 10060 | <1% | 31 | $4K | |
| 86900 | <1% | 4,326 | $4K | |
| 64447 | <1% | 33 | $4K | |
| 99386 | <1% | 33 | $4K | |
| 12002 | <1% | 12 | $4K | |
| 99152 | <1% | 1,876 | $4K | |
| 90633 | <1% | 546 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,580 | $4K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,345 | $4K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 819 | $4K |
| 87070 | <1% | 4,831 | $3K | |
| 85610 | <1% | 5,556 | $3K | |
| 91320 | <1% | 60 | $3K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 1,041 | $3K |
| 80050 | General health panel | <1% | 498 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 742 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,155 | $3K |
| 76870 | <1% | 31 | $3K | |
| 80143 | <1% | 845 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 829 | $3K |
| 90620 | <1% | 259 | $3K | |
| 90734 | <1% | 462 | $3K | |
| 99381 | <1% | 17 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,064 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,879 | $3K |
| 97802 | <1% | 46 | $2K | |
| 83735 | <1% | 8,510 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,624 | $2K |
| 90656 | <1% | 454 | $2K | |
| 88307 | <1% | 237 | $2K | |
| 76937 | <1% | 77 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,187 | $2K |
| 86901 | <1% | 4,323 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 19 | $2K |
| 80179 | <1% | 791 | $2K | |
| 90670 | <1% | 227 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 13,980 | $2K |
| G0400 | Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | <1% | 17 | $2K |
| 82565 | <1% | 669 | $2K | |
| 74022 | <1% | 225 | $2K | |
| 90750 | <1% | 30 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,526 | $2K |
| 87186 | <1% | 3,315 | $2K | |
| G0010 | Administration of hepatitis b vaccine | <1% | 304 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,403 | $2K |
| 84145 | <1% | 455 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,409 | $2K |
| 96376 | <1% | 6,808 | $2K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 13 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,240 | $2K |
| 90716 | <1% | 144 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,014 | $1K |
| 90697 | <1% | 223 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,798 | $1K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 19 | $1K |
| 0042T | <1% | 17 | $1K | |
| 90696 | <1% | 194 | $1K | |
| 90710 | <1% | 191 | $1K | |
| 90698 | <1% | 204 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,352 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,873 | $1K |
| 90681 | <1% | 164 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 10,072 | $1K |
| 84702 | <1% | 2,456 | $1K | |
| 74220 | <1% | 25 | $1K | |
| 90480 | <1% | 62 | $1K | |
| 82550 | <1% | 5,532 | $1K | |
| 87077 | <1% | 3,545 | $1K | |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | <1% | 42 | $990.59 |
| 96161 | <1% | 51 | $979.02 | |
| 85730 | <1% | 1,155 | $975.02 | |
| 90744 | <1% | 134 | $947.14 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,825 | $940.15 |
| 90700 | <1% | 128 | $930.41 | |
| 97016 | <1% | 35 | $907.54 | |
| 73140 | <1% | 148 | $886.02 | |
| 81003 | <1% | 2,323 | $878.46 | |
| 87210 | <1% | 3,276 | $849.81 | |
| 73590 | <1% | 91 | $833.12 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 35 | $811.75 |
| 72072 | <1% | 136 | $809.35 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,839 | $773.18 |
| 90653 | <1% | 228 | $732.02 | |
| 90694 | <1% | 116 | $717.36 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 683 | $712.37 |
| 85018 | <1% | 1,081 | $686.35 | |
| 77062 | <1% | 40 | $615.56 | |
| 90707 | <1% | 90 | $605.02 | |
| 80061 | Lipid panel | <1% | 388 | $599.29 |
| 84100 | <1% | 813 | $575.37 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 203 | $526.23 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 105 | $511.93 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,293 | $501.23 |
| 10061 | <1% | 13 | $465.55 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,403 | $451.80 |
| 87147 | <1% | 1,322 | $432.19 | |
| 82077 | <1% | 2,020 | $404.63 | |
| C1776 | Joint device (implantable) | <1% | 37 | $360.95 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,634 | $356.57 |
| 96367 | <1% | 91 | $339.54 | |
| C1769 | Guide wire | <1% | 1,596 | $302.46 |
| 82803 | <1% | 1,529 | $298.47 | |
| 84703 | <1% | 2,154 | $285.72 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,372 | $278.87 |
| 74019 | <1% | 64 | $278.79 | |
| 87634 | <1% | 364 | $237.23 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,622 | $229.31 |
| 71101 | <1% | 72 | $222.72 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 775 | $201.57 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,564 | $187.75 |
| 92567 | <1% | 41 | $175.57 | |
| 88342 | <1% | 1,046 | $149.01 | |
| 87807 | <1% | 680 | $148.95 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 923 | $147.70 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,379 | $144.67 |
| 90647 | <1% | 14 | $134.20 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,589 | $116.07 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 63 | $115.78 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,762 | $113.56 |
| 92552 | <1% | 130 | $106.01 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 405 | $100.74 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 163 | $99.20 |
| 93296 | <1% | 14 | $81.96 | |
| 82947 | <1% | 1,057 | $76.27 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,223 | $71.55 |
| 82330 | <1% | 1,097 | $68.16 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,040 | $66.26 |
| 36600 | <1% | 19 | $50.07 | |
| 99173 | <1% | 66 | $41.01 | |
| 82570 | <1% | 91 | $38.87 | |
| 90381 | <1% | 13 | $33.99 | |
| 81002 | <1% | 197 | $33.22 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 282 | $27.90 |
| 84132 | <1% | 1,172 | $27.81 | |
| 84295 | <1% | 1,005 | $25.10 | |
| 87205 | <1% | 180 | $23.40 | |
| 87088 | <1% | 215 | $21.49 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,387 | $20.01 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 558 | $19.29 |
| 85014 | <1% | 50 | $19.22 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 591 | $19.07 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 264 | $15.38 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 571 | $14.10 |
| 84156 | <1% | 31 | $13.31 | |
| 83615 | <1% | 14 | $10.94 | |
| 84550 | <1% | 27 | $8.02 | |
| 85652 | <1% | 146 | $7.76 | |
| 73080 | <1% | 25 | $5.47 | |
| 94760 | <1% | 1,393 | $5.43 | |
| 82272 | <1% | 28 | $5.33 | |
| 94762 | <1% | 254 | $4.56 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 43 | $4.25 |
| 94761 | <1% | 502 | $3.19 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 61 | $2.00 |
| J2720 | Injection, protamine sulfate, per 10 mg | <1% | 18 | $1.01 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 334 | $0.77 |
| A4565 | Slings | <1% | 194 | $0.26 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 653 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 1,008 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 180 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 210 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 65 | $0.00 |
| A9270 | Non-covered item or service | 0% | 3,436 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 27 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 109 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 67 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 17 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 20 | $0.00 |
| 72020 | 0% | 13 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 0% | 28 | $0.00 |
| 96368 | 0% | 15 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 41 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 14 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 672 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 377 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 918 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 186 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 220 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 228 | $0.00 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0% | 46 | $0.00 |
| C1876 | Stent, non-coated/non-covered, with delivery system | 0% | 40 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 774 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 70 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 106 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 46 | $0.00 |
| 76000 | 0% | 12 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.